• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

James C. Cusack, MD


  • Sahani DV, Bajwa MA, Andrabi Y, Bajpai S, Cusack JC.Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma.Ann Surg. 2014 May;259(5):861-72.
  • Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS.Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.J Gastrointest Cancer. 2014 Mar;45(1):34-9.
  • Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC.CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma.Mol Cancer Ther. 2013 Apr 24.
  • Santamaria-Barria JA, Boland GM, Yeap BY, Nardi V, Dias-Santagata D, Cusack JC.Merkel cell carcinoma: 30-year experience from a single institution.Ann Surg Oncol. 2013 Apr;20(4):1365-73.
  • Conrad C, Podolsky MJ, Cusack JC.Antiproteasomal agents in rectal cancer.Anti Cancer Drugs. 2011 Apr;22(4):341-50.
  • Cusack JC, Clark JW, Curley SA, Sahani DV, Zukerberg LR.Case records of the Massachusetts General Hospital: Case 3-2011: a 58-year-old woman with a mass in the liver.N Engl J Med. 2011 Jan 27;364(4):362-70.
  • Klos CL, Shellito PC, Rattner DW, Hodin RA, Cusack JC, Bordeianou L, Sylla P, Hong TS, Blaszkowsky L, Ryan DP, Lauwers GY, Chang Y, Berger DL.The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal cancer surgery.Am J Surg. 2010 Oct;200(4):440-5.
  • Sloss CM, Wang F, Palladino MA, Cusack JC.Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells.Oncogene. 2010 May 27;29(21):3146-52.
  • Sloss CM, Wang F, Palladino, MA, Cusack JC.Activation of EGFR by proteasome inhibition requires heparin-binding EGF-like growth factor (HB-EGF) in pancreatic cancer cells.Oncogene..
  • Sloss CM,Wang F,Liu R,Xia L,Houston M,Ljungman D,Palladino MA,Cusack JC Jr.Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.Clin Cancer Res. 2008 Aug 15;14(16):5116-23.
  • Donahue J,Sahani D,Tso L,Cusack JC Jr.Extra-adrenal pheochromocytoma involving the organ of Zuckerkandl.Surgery. 2008 Jun;143(6):830-2.
  • Wang F, Sloss C, Zhang X, Lee SW, Cusack JC.Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells.Cancer Res. 2007 Sep 15;67(18):8486-93.
  • Cusack JC, Liu R, Xia L, Chao TH, Pien C, Niu W, Palombella VJ, Neuteboom ST, Palladino MA.NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.Clin Cancer Res. 2006 Nov 15;12(22):6758-64.
  • Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC.A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.Cancer. 2006 Dec 1;107(11):2688-97.
  • Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J, Eder JP.Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.Cancer. 2006 Nov 15;107(10):2482-9.
  • Cusack JC.Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver.Ann Surg Oncol. 2003 Oct;10(8):852-62.
  • Cusack JC.Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.Cancer Treat Rev. 2003 May;29 Suppl 1:21-31.
  • Cusack JC.Clinical trials for cancer gene therapy.Surg Oncol Clin N Am. 2002 Jul;11(3):717-825.
  • Cusack JC, Tanabe KK.Introduction to cancer gene therapy.Surg Oncol Clin N Am. 2002 Jul;11(3):497-519, v.